title: 2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress.
abstract: Overexpression of the tumor suppressor gene, wild-type p53 (wtp53), using adenoviral vectors (Adp53) has been suggested to kill cancer cells by hydroperoxide-mediated oxidative stress [1,2] and nutrient distress induced by the glucose analog, 2-deoxyglucose (2DG), has been suggested to enhance tumor cell killing by agents that induce oxidative stress via disrupting hydroperoxide metabolism [3,4]. In the current study clonogenic cell killing of PC-3 and DU-145 human prostate cancer cells (lacking functional p53) mediated by 4 h exposure to 50 plaque forming units (pfus)/cell of Adp53 (that caused the enforced overexpression of wtp53) was significantly enhanced by treatment with 2DG. Accumulation of glutathione disulfide was found to be significantly greater in both cell lines treated with 2DG+Adp53 and both cell lines treated with 2DG+Adp53 showed a approximately 2-fold increases in dihydroethidine (DHE) and 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (CDCFH(2)) oxidation, indicative of increased steady-state levels of O(2)(.-) and hydroperoxides, respectively. Finally, overexpression of catalase or glutathione peroxidase using adenoviral vectors partially, but significantly, protected DU-145 cells from the toxicity induced by 2DG+Adp53 treatment. These results show that treatment of human prostate cancer cells with the combination of 2DG (a nutrient stress) and overexpression of the tumor suppressor gene, wtp53, enhances clonogenic cell killing by a mechanism that involves oxidative stress as well as allowing for the speculation that inhibitors of glucose and hydroperoxide metabolism can be used in combination with Adp53 gene therapy to enhance therapeutic responses.
authors.affiliation: Department of Radiography, The Hashemite University, Al-Zarqa', Jordan.
authors.forename: Iman M
authors.initials: IM
authors.lastname: Ahmad
authors.forename: Maher Y
authors.initials: MY
authors.lastname: Abdalla
authors.forename: Nukhet
authors.initials: N
authors.lastname: Aykin-Burns
authors.forename: Andrean L
authors.initials: AL
authors.lastname: Simons
authors.forename: Larry W
authors.initials: LW
authors.lastname: Oberley
authors.forename: Frederick E
authors.initials: FE
authors.lastname: Domann
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Spitz
mesh_terms: D000963:Antimetabolites / Q000627:therapeutic use*; D015153:Blotting, Western; D002374:Catalase / Q000378:metabolism; D003131:Combined Modality Therapy; D003847:Deoxyglucose / Q000627:therapeutic use*; D005434:Flow Cytometry; D015870:Gene Expression; D015316:Genetic Therapy; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D006801:Humans; D008297:Male; D018384:Oxidative Stress; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D000963:Antimetabolites; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D003847:Deoxyglucose; D002374:Catalase; D005979:Glutathione Peroxidase; D005978:Glutathione